Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vical blames credit crunch for job cuts

This article was originally published in Scrip

Executive Summary

Vical, a US-based biopharmaceutical company, is to cut its staff by 20%, leaving around 120 employees working for the company. It expects the cost-reduction initiative, which also involves the accelerated closure of a research facility, to reduce future net losses and cash burn by around $4 million annually. In the current economic climate, Vectura needs to reduce spending and focus its efforts on advancing its two late-stage product development programmes, Vijay Samant, the company's president and CEO, said. Allovectin-7, an immunotherapeutic, is currently in a Phase III trial in patients with advanced, metastatic melanoma and a DNA vaccine for cytomegalovirus is currently in Phase II trials in stem cell transplant recipients. Vectura expects to incur restructuring charges of around $800,000 in the fourth quarter of this year and an additional $500,000 in the first quarter of next year related to the facility's closure.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts